# Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

> **NCT03728361** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dwight Owen** · enrollment: 55 (actual)

## Conditions studied

- Grade I Neuroendocrine Carcinoma
- Grade II Neuroendocrine Carcinoma
- Grade III Neuroendocrine Carcinoma
- Metastatic Neuroendocrine Carcinoma
- Neuroendocrine Carcinoma
- Recurrent Small Cell Lung Carcinoma
- Refractory Small Cell Lung Carcinoma
- Lung Cancer Stage IV
- Large Cell Neuroendocrine Carcinoma
- Neuroendocrine Tumors
- Small Cell Lung Cancer Metastatic
- Small-cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03728361
- **Lead sponsor:** Dwight Owen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-31
- **Primary completion:** 2025-12-17
- **Final completion:** 2026-10-31
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03728361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03728361, "Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03728361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*